Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jie-du granule (also known as Jiedu granule or JDG) is a traditional Chinese medicine (TCM) herbal compound formulation developed by the Department of Traditional Chinese Medicine (Integrative Oncology) at Changhai Hospital (Second Military Medical University) in Shanghai, China. It is composed of four main herbal ingredients: Salvia chinensis Benth, Actinidia valvata, Cremastra appendiculata, and Gallus gallus domesticus (gizzard membrane) in a 1:1:0.4:0.4 ratio. Jie-du granule is primarily developed for the treatment of advanced hepatocellular carcinoma (HCC). It has been evaluated in clinical trials and retrospective cohort studies, both as a monotherapy and in combination with transcatheter arterial chemoembolization (TACE), gamma knife radiosurgery (GKR), or sorafenib, demonstrating potential to prolong overall survival and modulate gut microbiota in patients with advanced HCC.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jie-du granule.